目的:本研究从细胞因子角度出发探讨白介素-13(Interleukin-13,IL-13)、转化生子因子-β1(Transforming growthfactor-β1,TGF-β1)、血管内皮生子因子(Vascular endothelial growth factor,VEGF)血清浓度是否在哮喘患者的气道慢性炎症...目的:本研究从细胞因子角度出发探讨白介素-13(Interleukin-13,IL-13)、转化生子因子-β1(Transforming growthfactor-β1,TGF-β1)、血管内皮生子因子(Vascular endothelial growth factor,VEGF)血清浓度是否在哮喘患者的气道慢性炎症及重塑的发病机制中起着调控作用及其可能途径。方法:选择哮喘急性发作期患者36例(中重度发作20例、轻度发作16例)、缓解期36例、健康体检者36例。取肘静脉血,用ELISA方法测定血清中IL-13、TGF-β1、VEGF水平;所有入试者均作肺功能检查,并对结果进行统计学分析。结果:血清IL-13、TGF-β1、VEGF的表达量在哮喘患者中存在显著的正相关性;同时三者血清浓度越高,肺功能检查指标第1 s用力呼气容积(Forced expiratory volume in the 1st s,FEV1)、第1 s用力呼气容积占用力肺活量的比值(Ratio of forced expiratory volume in 1 s to forced vital capacity,FEV1/FVC%)越小,提示哮喘的病情程度越重,血清IL-13、TGF-β1、VEGF的表达量与FEV1、FEV1/FVC%呈负相关性。结论:IL-13、TGF-β1、VEGF网络失衡是哮喘发病的主要机制之一,三者在哮喘发病中相互影响,相互促进,共同参与哮喘的气道炎症与重塑的过程;联合检测血清IL-13、TGF-β1、VEGF水平对判断哮喘患者病情严重程度及预后、辅助诊断及治疗具有重要价值。展开更多
Background Genetic factors are believed to play a role in the individual susceptibility to chronic obstructive pulmonary disease (COPD). A single nucleotide polymorphism (SNP) of tumour necrosis factor-α (TNF-α) has...Background Genetic factors are believed to play a role in the individual susceptibility to chronic obstructive pulmonary disease (COPD). A single nucleotide polymorphism (SNP) of tumour necrosis factor-α (TNF-α) has been reported but inconsistent results may arise from different populations and phenotypes of COPD. There are only a few published studies of interleukin-13 (IL-13) SNPs on COPD. The SNPs of TNF-α and IL-13 have not been studied in the Chinese population. This research was conducted to study the frequencies of IL-13 gene promoter 1055 (IL-13-1055) and TNF-α gene-308 polymorphisms in the patients with COPD and to investigate the effect of those genetic polymorphisms on COPD in the Chinese population.Methods A cohort of COPD patients and age matched controls were recruited from an inpatient hospital service in Beijing. Venous blood was obtained and genomic DNA was extracted from peripheral blood monocytes using standard method. Genomic DNA was used as a template for amplification by polymerase chain reaction (PCR) to determine the polymorphism at -1055 in the IL-13 gene promoter region. PCR restriction fragment length polymorphism (RFLP) was used to determine polymorphisms in the TNF-α gene-308 position. The products were investigated by sequence analysis also. Results One hundred and eleven COPD patients and 97 controls were studied. Seventy-five cases were current smokers in COPD patients and 36 were current smokers in controls. The frequencies of TT genotype in the IL-13 gene promoter region were 11.7% (13/111) in the COPD group and 13.4% (13/97) in the controls (P=0.713). However, the OR value of TT genotype was significantly increased to 6.4 (95% CI 1.62-25.39) in the smokers with COPD. TT genotype was also positively related to family history of COPD, OR=7.7 (95% CI 1.37-43.80). The frequencies of A allele in the TNF-α gene were 5.9% in COPD and 3.1% in controls (P=0.131). The OR value of A allele was 5.0 (95% CI 1.011 to 25.059) in smokers with COPD. Conclusions There is no significant diff展开更多
目的在临床实际应用中,对2020年6月在中国被批准用于治疗中重度特应性皮炎(atopic dermatitis,AD)患者的度普利尤单抗的有效性和安全性进行评估。方法对20例经局部和/或全身用药控制不佳的中重度AD患者采用度普利尤单抗皮下注射治疗满1...目的在临床实际应用中,对2020年6月在中国被批准用于治疗中重度特应性皮炎(atopic dermatitis,AD)患者的度普利尤单抗的有效性和安全性进行评估。方法对20例经局部和/或全身用药控制不佳的中重度AD患者采用度普利尤单抗皮下注射治疗满16周。评估湿疹面积和严重程度指数(eczema area and severity index,EASI)、瘙痒数值评分量表(numerical,NRS)评分变化,及其与总IgE和嗜酸性粒细胞水平的相关性,以及该药的安全性。结果基线时(第0周)和治疗后第4、8和16周时的平均EASI评分(±标准差)分别为(28.4±9.9),(12.8±7.3),(7.8±6.6)和(4.3±4.4);基线期和治疗后第4、8和16周时的瘙痒平均NRS评分(±标准差)分别为(8.1±1.2),(4.7±1.5),(3.6±1.4)和(2.3±1.2)。本研究未发现总IgE和嗜酸性粒细胞水平与疗效变化的相关性。20例患者治疗过程及随访中未出现显著不良反应。结论度普利尤单抗能显著改善中重度AD患者的EASI评分和瘙痒NRS评分,且具有良好的安全性。展开更多
文摘目的:本研究从细胞因子角度出发探讨白介素-13(Interleukin-13,IL-13)、转化生子因子-β1(Transforming growthfactor-β1,TGF-β1)、血管内皮生子因子(Vascular endothelial growth factor,VEGF)血清浓度是否在哮喘患者的气道慢性炎症及重塑的发病机制中起着调控作用及其可能途径。方法:选择哮喘急性发作期患者36例(中重度发作20例、轻度发作16例)、缓解期36例、健康体检者36例。取肘静脉血,用ELISA方法测定血清中IL-13、TGF-β1、VEGF水平;所有入试者均作肺功能检查,并对结果进行统计学分析。结果:血清IL-13、TGF-β1、VEGF的表达量在哮喘患者中存在显著的正相关性;同时三者血清浓度越高,肺功能检查指标第1 s用力呼气容积(Forced expiratory volume in the 1st s,FEV1)、第1 s用力呼气容积占用力肺活量的比值(Ratio of forced expiratory volume in 1 s to forced vital capacity,FEV1/FVC%)越小,提示哮喘的病情程度越重,血清IL-13、TGF-β1、VEGF的表达量与FEV1、FEV1/FVC%呈负相关性。结论:IL-13、TGF-β1、VEGF网络失衡是哮喘发病的主要机制之一,三者在哮喘发病中相互影响,相互促进,共同参与哮喘的气道炎症与重塑的过程;联合检测血清IL-13、TGF-β1、VEGF水平对判断哮喘患者病情严重程度及预后、辅助诊断及治疗具有重要价值。
文摘Background Genetic factors are believed to play a role in the individual susceptibility to chronic obstructive pulmonary disease (COPD). A single nucleotide polymorphism (SNP) of tumour necrosis factor-α (TNF-α) has been reported but inconsistent results may arise from different populations and phenotypes of COPD. There are only a few published studies of interleukin-13 (IL-13) SNPs on COPD. The SNPs of TNF-α and IL-13 have not been studied in the Chinese population. This research was conducted to study the frequencies of IL-13 gene promoter 1055 (IL-13-1055) and TNF-α gene-308 polymorphisms in the patients with COPD and to investigate the effect of those genetic polymorphisms on COPD in the Chinese population.Methods A cohort of COPD patients and age matched controls were recruited from an inpatient hospital service in Beijing. Venous blood was obtained and genomic DNA was extracted from peripheral blood monocytes using standard method. Genomic DNA was used as a template for amplification by polymerase chain reaction (PCR) to determine the polymorphism at -1055 in the IL-13 gene promoter region. PCR restriction fragment length polymorphism (RFLP) was used to determine polymorphisms in the TNF-α gene-308 position. The products were investigated by sequence analysis also. Results One hundred and eleven COPD patients and 97 controls were studied. Seventy-five cases were current smokers in COPD patients and 36 were current smokers in controls. The frequencies of TT genotype in the IL-13 gene promoter region were 11.7% (13/111) in the COPD group and 13.4% (13/97) in the controls (P=0.713). However, the OR value of TT genotype was significantly increased to 6.4 (95% CI 1.62-25.39) in the smokers with COPD. TT genotype was also positively related to family history of COPD, OR=7.7 (95% CI 1.37-43.80). The frequencies of A allele in the TNF-α gene were 5.9% in COPD and 3.1% in controls (P=0.131). The OR value of A allele was 5.0 (95% CI 1.011 to 25.059) in smokers with COPD. Conclusions There is no significant diff
文摘目的在临床实际应用中,对2020年6月在中国被批准用于治疗中重度特应性皮炎(atopic dermatitis,AD)患者的度普利尤单抗的有效性和安全性进行评估。方法对20例经局部和/或全身用药控制不佳的中重度AD患者采用度普利尤单抗皮下注射治疗满16周。评估湿疹面积和严重程度指数(eczema area and severity index,EASI)、瘙痒数值评分量表(numerical,NRS)评分变化,及其与总IgE和嗜酸性粒细胞水平的相关性,以及该药的安全性。结果基线时(第0周)和治疗后第4、8和16周时的平均EASI评分(±标准差)分别为(28.4±9.9),(12.8±7.3),(7.8±6.6)和(4.3±4.4);基线期和治疗后第4、8和16周时的瘙痒平均NRS评分(±标准差)分别为(8.1±1.2),(4.7±1.5),(3.6±1.4)和(2.3±1.2)。本研究未发现总IgE和嗜酸性粒细胞水平与疗效变化的相关性。20例患者治疗过程及随访中未出现显著不良反应。结论度普利尤单抗能显著改善中重度AD患者的EASI评分和瘙痒NRS评分,且具有良好的安全性。
